IRIS Accounts Production v26.1.10.61 10644937 Board of Directors 1.12.24 30.11.25 30.11.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106449372024-11-30106449372025-11-30106449372024-12-012025-11-30106449372023-11-30106449372023-12-012024-11-30106449372024-11-3010644937ns15:EnglandWales2024-12-012025-11-3010644937ns14:PoundSterling2024-12-012025-11-3010644937ns10:Director12024-12-012025-11-3010644937ns10:PrivateLimitedCompanyLtd2024-12-012025-11-3010644937ns10:SmallEntities2024-12-012025-11-3010644937ns10:AuditExempt-NoAccountantsReport2024-12-012025-11-3010644937ns10:SmallCompaniesRegimeForDirectorsReport2024-12-012025-11-3010644937ns10:SmallCompaniesRegimeForAccounts2024-12-012025-11-3010644937ns10:FullAccounts2024-12-012025-11-301064493712024-12-012025-11-3010644937ns10:Director22024-12-012025-11-3010644937ns10:RegisteredOffice2024-12-012025-11-3010644937ns5:CurrentFinancialInstruments2025-11-3010644937ns5:CurrentFinancialInstruments2024-11-3010644937ns5:ShareCapital2025-11-3010644937ns5:ShareCapital2024-11-3010644937ns5:RetainedEarningsAccumulatedLosses2025-11-3010644937ns5:RetainedEarningsAccumulatedLosses2024-11-3010644937ns5:NetGoodwill2024-12-012025-11-3010644937ns5:NetGoodwill2024-11-3010644937ns5:NetGoodwill2025-11-3010644937ns5:NetGoodwill2024-11-3010644937ns5:LandBuildings2024-11-3010644937ns5:FurnitureFittings2024-11-3010644937ns5:ComputerEquipment2024-11-3010644937ns5:LandBuildings2024-12-012025-11-3010644937ns5:FurnitureFittings2024-12-012025-11-3010644937ns5:ComputerEquipment2024-12-012025-11-3010644937ns5:LandBuildings2025-11-3010644937ns5:FurnitureFittings2025-11-3010644937ns5:ComputerEquipment2025-11-3010644937ns5:LandBuildings2024-11-3010644937ns5:FurnitureFittings2024-11-3010644937ns5:ComputerEquipment2024-11-3010644937ns5:WithinOneYearns5:CurrentFinancialInstruments2025-11-3010644937ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-30
REGISTERED NUMBER: 10644937 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 November 2025

for

Queens Road Pharma Limited

Queens Road Pharma Limited (Registered number: 10644937)






Contents of the Financial Statements
for the Year Ended 30 November 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Queens Road Pharma Limited

Company Information
for the Year Ended 30 November 2025







DIRECTORS: S Patel
Miss R K Raghwani





REGISTERED OFFICE: 39 Bromley Road
Catford
London
SE6 2TS





REGISTERED NUMBER: 10644937 (England and Wales)





ACCOUNTANTS: Kallis LLP
Chartered Certified Accountant
22 Westward Way
Harrow
Middlesex
HA3 0SE

Queens Road Pharma Limited (Registered number: 10644937)

Balance Sheet
30 November 2025

30.11.25 30.11.24
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 83,334 122,134
Tangible assets 5 1,037,819 1,059,850
1,121,153 1,181,984

CURRENT ASSETS
Stocks 6 74,653 85,646
Debtors 7 97,230 78,264
Cash at bank and in hand 191,452 43,565
363,335 207,475
CREDITORS
Amounts falling due within one year 8 261,340 449,328
NET CURRENT ASSETS/(LIABILITIES) 101,995 (241,853 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,223,148

940,131

CAPITAL AND RESERVES
Called up share capital 10 10
Retained earnings 1,223,138 940,121
SHAREHOLDERS' FUNDS 1,223,148 940,131

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Queens Road Pharma Limited (Registered number: 10644937)

Balance Sheet - continued
30 November 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 August 2026 and were signed on its behalf by:





S Patel - Director


Queens Road Pharma Limited (Registered number: 10644937)

Notes to the Financial Statements
for the Year Ended 30 November 2025

1. STATUTORY INFORMATION

Queens Road Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Purchased goodwill is initially recognised at cost. After recognition purchased goodwill is amortised over its expected useful life and measured at cost less accumulated amortisation.
Goodwill is considered to have a finite useful life. If a reliable estimate of the useful cannot be made, the useful life shall not exceeds 10 years.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.Cost includes costs directly attributable to making the asset capable of operating as intended.Depreciation is provided on all tangible fixed assets,except land, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful lie as follows:

Freehold Property :2% on costs
Fixture, Fittings and equipments: 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Queens Road Pharma Limited (Registered number: 10644937)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 9 (2024 - 11 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2024
and 30 November 2025 388,000
AMORTISATION
At 1 December 2024 265,866
Charge for year 38,800
At 30 November 2025 304,666
NET BOOK VALUE
At 30 November 2025 83,334
At 30 November 2024 122,134

Queens Road Pharma Limited (Registered number: 10644937)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2025

5. TANGIBLE FIXED ASSETS
Fixtures
Freehold and Computer
property fittings equipment Totals
£    £    £    £   
COST
At 1 December 2024 1,048,696 56,931 4,035 1,109,662
Additions - 9,300 - 9,300
At 30 November 2025 1,048,696 66,231 4,035 1,118,962
DEPRECIATION
At 1 December 2024 20,974 26,462 2,376 49,812
Charge for year 20,974 9,942 415 31,331
At 30 November 2025 41,948 36,404 2,791 81,143
NET BOOK VALUE
At 30 November 2025 1,006,748 29,827 1,244 1,037,819
At 30 November 2024 1,027,722 30,469 1,659 1,059,850

6. STOCKS
30.11.25 30.11.24
£    £   
Stocks 74,653 85,646

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.25 30.11.24
£    £   
Trade debtors 55,784 60,681
VAT 34,627 13,931
Prepayments 6,819 3,652
97,230 78,264

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.25 30.11.24
£    £   
Trade creditors 123,989 133,364
Tax 114,616 97,741
Other creditors - 195,000
Directors loan accounts 10,025 8,929
Accrued expenses 12,710 14,294
261,340 449,328